Drugs / V184
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03807843 | Jul 2019 → May 2021 | chikungunya | Themis Bioscience GmbH | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | V184 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03807843 ↗ |
| Modality | Vaccine | “Recombinant live Schwarz-strain measles-vectored vaccine expressing chikungunya virus structural proteins.” NCT03807843 ↗ |
| Route | Intramuscular | “administered via IM injection” NCT03807843 ↗ |